|
Video: What is a Stock Split?
|
|
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S. According to our MDGL split history records, Madrigal Pharmaceuticals has had 1 split. | |
|
Madrigal Pharmaceuticals (MDGL) has 1 split in our MDGL split history database. The split for MDGL took place on July 25, 2016. This was a 1 for 35 reverse split, meaning for each 35 shares of MDGL owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 28.5714285714286 share position following the split.
When a company such as Madrigal Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the MDGL split history from start to finish, an original position size of 1000 shares would have turned into 28.5714285714286 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Madrigal Pharmaceuticals shares, starting with a $10,000 purchase of MDGL, presented on a split-history-adjusted basis factoring in the complete MDGL split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/07/2014 |
|
End date: |
10/03/2024 |
|
Start price/share: |
$101.15 |
|
End price/share: |
$206.58 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
104.23% |
|
Average Annual Total Return: |
7.40% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$20,415.40 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
07/25/2016 | 1 for 35 |
|
|